
# Table 1. Classes of interventions

|Nonsteroidal antiinflammatory drugs|Any at therapeutic dosing (ibuprofen, naproxen, tolmetin, indomethacin, meloxicam, nabumetone, diclofenac, piroxicam, etodolac, celecoxib)|
|---|---|
|Conventional synthetic disease-modifying antirheumatic drugs|Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, calcineurin inhibitors (cyclosporin A, tacrolimus)|
|Biologic disease-modifying antirheumatic drugs|Tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol); other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)|
|Glucocorticoids|Oral (any); intravenous (any); intraarticular (triamcinolone acetonide, triamcinolone hexacetonide)|

# Table 2. Strength of recommendations and quality of supporting evidence*

|Condition|No. of recommendations|Conditional|Strong|Very low|Low|Moderate|High|
|---|---|---|---|---|---|---|---|
|Oligoarthritis|9|5|4|7|2|0|0|
|TMJ arthritis|7|6|1|7|0|0|0|
|Systemic JIA|9|5|4|9|0|0|0|
|Total|25|16|9|23|2|0|0|

* TMJ = temporomandibular joint; JIA = juvenile idiopathic arthritis.

# Table 3. Oligoarticular JIA*

|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s). of evidence tables†|
|---|---|---|---|
|A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy.|Very low|PICO 1. In children with oligoarticular JIA, should a trial of scheduled NSAIDs be recommended?|6–9|
|IAGCs are strongly recommended as part of initial therapy.|Very low|PICO 2. In children with oligoarticular JIA, should adding IAGCs to initial therapy be recommended?|10–19|
|Triamcinolone hexacetonide is strongly recommended as the preferred agent.|Low|PICO 4. In children with oligoarticular JIA, should a specific steroid type be recommended for intraarticular injection?|21–27|
|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 3. In children with oligoarticular JIA, should adding oral steroids to initial therapy be recommended?|19–20|
|Conventional synthetic DMARDs are strongly recommended if there is inadequate response to scheduled NSAIDs and/or IAGCs. MTX is conditionally recommended as a preferred agent over LEF, SSZ, and HCQ (in that order).|Low (MTX); Very low (LEF, SSZ, HCQ)|PICO 5. In children with oligoarticular JIA, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous or oral), LEF, SSZ, and/or HCQ?|28–41|
|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|
|There is no preferred biologic DMARD.| | | |
|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|
|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|

* JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor; TMJ = temporomandibular joint.

† In Supplementary Appendix 3, on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.

# Table 4. TMJ arthritis*

|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|
|---|---|---|---|
|A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy.|Very low|PICO 11. In children with JIA with active TMJ arthritis, should a trial of scheduled NSAIDs be recommended, and should there be any preferred NSAID treatment?|53|
|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|
|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|
|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|
|Conventional synthetic DMARDs are strongly recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs.|Very low|PICO 15. In children with JIA with active TMJ arthritis, should DMARD therapies be recommended, and should there be any preferred order of treatment: MTX (subcutaneous and oral), LEF, SSZ, and/or HCQ?|58–59|
|MTX is conditionally recommended as a preferred agent over LEF.| | | |
|Biologic DMARDs are conditionally recommended for inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 16. In children with JIA with active TMJ arthritis, should systemic biologic therapies be recommended, and should there be any preferred order of treatment: TNFi, biologic treatments with other mechanisms of action?|59|
|There is no preferred biologic agent.| | | |
|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|

* TMJ = temporomandibular joint; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; JIA = juvenile idiopathic arthritis; IAGCs = intraarticular glucocorticoids; DMARDs = disease-modifying antirheumatic drugs; MTX = methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ = hydroxychloroquine; TNFi = tumor necrosis factor inhibitor.

† In Supplementary Appendix 3, on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.


# Table 5. Systemic JIA without MAS*

|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|
|---|---|---|---|
|NSAIDs are conditionally recommended as initial monotherapy.|Very low|PICO 20. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should non-DMARD treatment (NSAIDs, glucocorticoids) be used as initial therapy?|61–67|
|Oral glucocorticoids are conditionally recommended against as initial monotherapy.| | | |
|Conventional synthetic DMARDs are strongly recommended against as initial monotherapy.|Very low|PICO 21. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should DMARD treatment (MTX, calcineurin inhibitor) be used as initial therapy, and is there a preferred order?|67–68|
|Biologic DMARDs (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy.|Very low|PICO 22. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should biologic treatment (anakinra, canakinumab, tocilizumab, or others) be used as initial therapy, and is there a preferred order?|69–71|
|There is no preferred agent.| | | |
|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|
|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|

* JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; NSAIDs = nonsteroidal antiinflammatory drugs; DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin.

† In Supplementary Appendix 3, on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.


# Table 6. Systemic JIA with MAS*

|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|
|---|---|---|---|
|Formal recommendation deferred|Very low|PICO 24. In patients with systemic JIA, does the presence of subclinical MAS alter the treatment paradigm?|130|
|IL-1 and IL-6 inhibitors are conditionally recommended over calcineurin inhibitors alone to achieve inactive disease and resolution of MAS.|Very low|PICO 25. In patients with systemic JIA and overt MAS, is biologic therapy superior to calcineurin inhibitors for achievement of inactive disease and resolution of MAS?|131–136|
|Glucocorticoids are conditionally recommended as part of initial treatment of systemic JIA with MAS. There is no preferred agent.| | | |
|Formal recommendation deferred|Very low|PICO 26. For nonresponse or partial response to biologic therapy, is addition of a calcineurin inhibitor superior to etoposide or IVIG or plasmapheresis for achievement of inactive disease and resolution of MAS?|137–138|
|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or mesenchymal stem cell transplant or bone marrow transplant) for achievement of inactive disease, achievement of partial response, growth, ability to taper/discontinue steroids, and minimization of side effects/medication toxicity?|138|

* JIA = juvenile idiopathic arthritis; MAS = macrophage activation syndrome; PICO = Patient/Population, Intervention, Comparison, and Outcomes; IL-1 = interleukin-1; IVIG = intravenous immunoglobulin; DMARDs = disease-modifying antirheumatic drugs.

† In Supplementary Appendix 3, on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.

# Table 7. Systemic JIA with inactive disease*

|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|
|---|---|---|---|
|Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained.|Very low|PICO 28. In patients with systemic JIA with inactive disease treated with oral steroids, is taper to discontinuation of steroids superior to continuing long-term stable-dose steroids for preventing disease flare and minimizing side effects/medication toxicity?|139|
|Tapering and discontinuing biologic DMARDs is conditionally recommended after inactive disease has been attained.|Very low|PICO 29. In patients with systemic JIA in clinical remission with biologic monotherapy, is tapering by decreasing dosage superior to tapering dosing interval at preventing disease exacerbation, preventing development of antidrug antibodies, and minimizing medication toxicity?|140–143|

* JIA = juvenile idiopathic arthritis; PICO = Patient/Population, Intervention, Comparison, and Outcomes; DMARDs = disease-modifying antirheumatic drugs.

† In Supplementary Appendix 3, on the Arthritis & Rheumatology website at https://onlinelibrary.wiley.com/doi/10.1002/art.42037/abstract.
